Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493352 | 1.00 | ACHE (0.38) | ACHEBACE1MCHR1LTA4HKDM4E | |
| SCHEMBL4488651 | 0.90 | ACHE (0.45) | ACHEMCHR1LTA4HTMEM97SIGMAR1 | |
| SCHEMBL4488657 | 0.90 | ACHE (0.45) | ACHEMCHR1LTA4HTMEM97SIGMAR1 | |
| SCHEMBL2570287 | 0.90 | ACHE (0.41) | ACHEMCHR1LTA4HKDM4E | |
| SCHEMBL30708647 | 0.90 | ACHE (0.41) | ACHEMCHR1LTA4HKDM4E | |
| SCHEMBL2570281 | 0.90 | ACHE (0.41) | ACHEMCHR1LTA4HKDM4E | |
| SCHEMBL4490416 | 0.87 | BACE1 (0.40) | ACHEBACE1LTA4HACKR3TMEM97 | |
| SCHEMBL4492313 | 0.87 | BACE1 (0.40) | ACHEBACE1LTA4HACKR3TMEM97 | |
| SCHEMBL4492319 | 0.87 | BACE1 (0.40) | ACHEBACE1LTA4HACKR3TMEM97 | |
| SCHEMBL4490412 | 0.87 | BACE1 (0.40) | ACHEBACE1LTA4HACKR3TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | ACHE 2967/4885BACE1 1615/4885MCHR1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.